Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised non-inferiority trial of DTG/3TC fixed-dose formulations for maintenance of virological suppression in children
2020-001426-57Phase 3Active
- Sponsor
- Penta Foundation
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Penta Foundation. Started Aug 2022; status: active.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-001426-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001426-57.